Icon

Neoleukin Therapeutics, Inc Stock Analysis and Price Target COMMON STOCK | Other | NSD

stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.03

0.00 (0.00)%

USD 0.10B

0.27M

N/A

N/A

Icon

AQXP

Neoleukin Therapeutics, Inc (USD)
COMMON STOCK | NSD
USD 4.03
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.10B

N/A

USD 4.03

Neoleukin Therapeutics, Inc Stock Forecast

N/A

Based on the Neoleukin Therapeutics, Inc stock forecast from 0 analysts, the average analyst target price for Neoleukin Therapeutics, Inc is not available over the next 12 months. Neoleukin Therapeutics, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Neoleukin Therapeutics, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Neoleukin Therapeutics, Inc’s stock price was USD 4.03. Neoleukin Therapeutics, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Neoleukin Therapeutics, Inc
No recent average analyst rating found for Neoleukin Therapeutics, Inc

Company Overview

Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aq...Read More

http://www.aqxpharma.com

887 Great Northern Way, Suite 450 V5T 4T5,Vancouver,CAN

8

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Neoleukin Therapeutics, Inc (Sector: Other )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY
Legacy Reserves Inc 0.00 (0.00%) USD61,525,874.67B 1.10 5.30

ETFs Containing AQXP

Symbol Name AQXP's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About AQXP Stock

Stock Target Advisor's fundamental analysis for Neoleukin Therapeutics, Inc's stock is Very Bearish.

Unfortunately we do not have enough data on AQXP's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AQXP's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on AQXP's stock to indicate if its overvalued.

The last closing price of AQXP's stock was USD 4.03.

The most recent market capitalization for AQXP is USD 0.10B.

Unfortunately we do not have enough analyst data on AQXP's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...